Sverre Holm

Sverre Holm

Auto-generated profile, based on publicly available information

Sverre Holm

Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2016 in Scientific Reports
Verified
Journal Article
Open access
TSTonje Skarpengland
Tonje Skarpengland
SHSverre Holm
Sverre Holm
KSKatja Scheffler
Katja Scheffler
IGIda Gregersen
Ida Gregersen
TDTuva Børresdatter Dahl
Tuva Børresdatter Dahl
PAPål Aukrust
Pål Aukrust
Increasing evidence suggests that oxidative DNA damage accumulates in atherosclerosis. Recently, we showed that a genetic variant in the human DNA repair enzyme NEIL3 was associated with increased risk of myocardial infarction. Here, we explored the role of Neil3/NEIL3 in atherogenesis by both clinical and experimental approaches. Human carotid plaques revealed increased NEIL3 mRNA expression which significantly correlated with mRNA levels of the macrophage marker CD68. Apoe−/−Neil3−/− mice on high-fat diet showed accelerated plaque formation as compared to Apoe−/− mice, reflecting an atherogenic lipid profile, increased hepatic triglyceride levels and attenuated macrophage cholesterol efflux capacity. Apoe−/−Neil3−/− mice showed marked alterations in several pathways affecting hepatic lipid metabolism, but no genotypic alterations in genome integrity or genome-wide accumulation of oxidative DNA damage. These results suggest a novel role for the DNA glycosylase Neil3 in atherogenesis in balancing lipid metabolism and macrophage function, potentially independently of genome-wide canonical base excision repair of oxidative DNA damage.

28 December 2015 in Expert Review of Cardiovascular Therapy
Verified
Journal Article
Closed access
IGIda Gregersen
Ida Gregersen
SHSverre Holm
Sverre Holm
TDTuva Børresdatter Dahl
Tuva Børresdatter Dahl
BHBente Evy Halvorsen
Bente Evy Halvorsen
PAPål Aukrust
Pål Aukrust
Atherosclerosis is a dynamic, pathogenic process in the artery wall, with potential adverse outcome for the host. Acute events such as myocardial infarction and ischemic stroke often result from ru...

4 February 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
MLMieke C. Louwe
Mieke C. Louwe
CGChrysostomi Gialeli
Chrysostomi Gialeli
AMAnnika Elisabet Michelsen
Annika Elisabet Michelsen
SHSverre Holm
Sverre Holm
AEAndreas Edsfeldt
Andreas Edsfeldt
BHBente Evy Halvorsen
Bente Evy Halvorsen
Background: Complement activation may promote atherosclerosis. Yet, data on the to which extent complement, and more specifically the alternative complement pathway, is activated in patients with carotid atherosclerosis and related to adverse outcome in these patients, are scarce. Methods and Results: We measured, by ELISA, plasma levels of factor D, properdin, C3bBbP (C3 convertase), and factor H in patients with advanced carotid atherosclerosis in a Discovery (n=324) and in a Validation (n=206) cohort in relation to adverse outcome (mean follow‐up 7.8 and 6.6 years, respectively). Our major findings were as follows. Compared with healthy controls, patients with carotid atherosclerosis had increased plasma levels of factor D, properdin, and C3bBbP ( P <0.001), but not factor H, an inhibitor of the alternative complement pathway, compared with controls. Although patients with carotid atherosclerosis had elevated levels of properdin compared with controls, within these patients, low plasma levels of properdin (ie, <median levels of properdin in the patient group) were significantly associated with cardiovascular mortality. This was seen in both the Discovery (HR 2.31, P =0.019) and the Validation cohort (hazard ratio [HR], 2.81, P =0.014). In contrast to the low circulating levels, high intraplaque properdin levels (assessed by ELISA) correlated with markers of plaque vulnerability and symptomatology. Conclusions: We show a strong and independent association of low plasma properdin levels with cardiovascular mortality in 2 cohorts. Conversely, the plaque properdin levels linked to features of plaque vulnerability, potentially reflecting increased deposition at the site of inflammation or local production of properdin in the atherosclerotic lesion indicating local enhanced alternative complement pathway activation.

18 January 2022 in Biochemistry and Biophysics Reports
Verified
Journal Article
Open access
TKTom Rune Karlsen
Tom Rune Karlsen
MOMaria B. Olsen
Maria B. Olsen
XKXiang Y. Kong
Xiang Y. Kong
KYKuan Yang
Kuan Yang
AQAna Quiles-Jiménez
Ana Quiles-Jiménez
BHBente Evy Halvorsen
Bente Evy Halvorsen
Deficiency of NEIL3, a DNA repair enzyme, has significant impact on mouse physiology, including vascular biology and gut health, processes related to aging. Leukocyte telomere length (LTL) is suggested as a marker of biological aging, and shortened LTL is associated with increased risk of cardiovascular disease. NEIL3 has been shown to repair DNA damage in telomere regions in vitro. Herein, we explored the role of NEIL3 in telomere maintenance in vivo by studying bone marrow cells from atherosclerosis-prone NEIL3-deficient mice. We found shortened telomeres and decreased activity of the telomerase enzyme in bone marrow cells derived from Apoe−/−Neil3−/− as compared to Apoe−/− mice. Furthermore, Apoe−/−Neil3−/− mice had decreased leukocyte levels as compared to Apoe−/− mice, both in bone marrow and in peripheral blood. Finally, RNA sequencing of bone marrow cells from Apoe−/−Neil3−/− and Apoe−/− mice revealed different expression levels of genes involved in cell cycle regulation, cellular senescence and telomere protection. This study points to NEIL3 as a telomere-protecting protein in murine bone marrow in vivo.

17 August 2024 in Scandinavian Journal of Clinical and Laboratory Investigation
Verified
Journal Article
Open access
SHS. Holm
S. Holm
AMA. E. Michelsen
A. E. Michelsen
NSN. H. Schultz
N. H. Schultz
TUT. Ueland
T. Ueland
HRH. Reikvam
H. Reikvam
BHBente Evy Halvorsen
Bente Evy Halvorsen

13 November 2022 in medRxiv
Verified
Preprint
Open access
PDF file
SSSiri Fløgstad Svensson
Siri Fløgstad Svensson
SHSkarphéðinn Halldórsson
Skarphéðinn Halldórsson
ALAnna Latysheva
Anna Latysheva
EFElies Fuster-Garcia
Elies Fuster-Garcia
THTrine Hjørnevik
Trine Hjørnevik
KEKyrre Emblem
Kyrre Emblem
Background: The biomechanical tissue properties of glioblastoma tumors are heterogeneous, but the molecular mechanisms involved and the biological implications are poorly understood. Here, we combine magnetic resonance elastography (MRE) measurement of tissue stiffness with RNA sequencing of tissue biopsies to explore the molecular characteristics of the stiffness signal. Methods: MRE was performed preoperatively in 13 patients with glioblastoma. Navigated biopsies were harvested during surgery and later classified as ‘stiff’ or ‘soft’ according to MRE stiffness measurements (|G*| norm ). Twenty-two biopsies from eight patients were analysed by RNA sequencing. Results: The mean whole-tumor stiffness was lower than in normal-appearing white matter. The surgeon’s biopsy stiffness evaluation did not correlate with the MRE measurements, which suggests that they measure different properties. Gene set enrichment analysis of the differentially expressed genes between ‘stiff’ and ‘soft’ biopsies showed that genes involved in extracellular matrix reorganization and cellular adhesion were overexpressed in ‘stiff’ biopsies. Supervised dimensionality reduction identified a gene expression signal separating ‘stiff ‘and ‘soft’ biopsies. Using the NIH Genomic Data Portal, 265 patients with glioblastoma were divided into patients with (n=63) and without (n=202) this gene expression signal. The median survival time of patients with tumors expressing the gene expression signal associated with ‘stiff’ biopsies was 100 days shorter than that of patients not expressing it (360 versus 460 days, hazard ratio: 1.45, P<0.05). Conclusion: MRE imaging of glioblastoma can provide non-invasive information on intratumoral heterogeneity. Regions of extracellular matrix reorganization showed an expression signal correlated to shorter survival time in patients with glioblastoma. Importance of the study: While the importance of biomechanical forces in glioblastoma is unquestioned, the underlying mechanisms are still not well understood, nor its clinical implications. Several methods exist to assess tissue stiffness, but MRE is unique in allowing measurements of stiffness in vivo and in situ . For the first time, we present molecular profiling of glioblastoma tissue correlated with in situ stiffness measurements. The transcriptomic profiles of ‘stiff’ and ‘soft’ biopsies showed that extracellular matrix reorganization was strongly associated with the ‘stiff’ biopsies, in particular collagen binding. Genes associated with innate immune processes were also upregulated in ‘stiff’ biopsies, indicating that these are active regions of the tumor. The association between gene expression in ‘stiff’ biopsies and survival is in concordance with previous reports of elevated extracellular matrix stiffness increasing glioblastoma aggression. Key Points: - MR Elastography can provide unique information on intratumoral heterogeneity preoperatively. - MR Elastography identifies tumor regions of active extracellular reorganization - Gene expression signal associated with increased stiffness negatively correlates with survival